Clinical Trial Update: A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports results from a long-term Phase 2/3 study of MP-214 in adults with chronic-phase or elderly schizophrenia, sponsored by Tanabe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MP-214

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-13